1. Assessing efficacy in important subgroups in confirmatory trials: An example using Bayesian dynamic borrowing. (21st January 2021) Authors: Best, Nicky; Price, Robert G.; Pouliquen, Isabelle J.; Keene, Oliver N. Journal: Pharmaceutical statistics Issue: Volume 20:Number 3(2021) Page Start: 551 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Differential solubility of subcomponents of rat glomerular basement membrane. Issue 4 (April 1984) Authors: Taylor, Sarah A.; Price, Robert G. Journal: Bioscience reports Issue: Volume 4:Issue 4(1984) Page Start: 319 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Evaluation of sputum eosinophil count as a predictor of treatment response to mepolizumab. Issue 2 (3rd May 2022) Authors: Pavord, Ian D.; Buhl, Roland; Kraft, Monica; Prazma, Charlene M.; Price, Robert G.; Howarth, Peter H.; Yancey, Steven W. Journal: ERJ open research Issue: Volume 8:Issue 2(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Health outcomes after stopping long-term mepolizumab in severe eosinophilic asthma: COMET. Issue 1 (10th January 2022) Authors: Liu, Mark C.; Bel, Elisabeth H.; Kornmann, Oliver; Moore, Wendy C.; Kaneko, Norihiro; Smith, Steven G.; Martin, Neil; Price, Robert G.; Yancey, Steven W.; Humbert, Marc Journal: ERJ open research Issue: Volume 8:Issue 1(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Macromolecular associations, antigenicity, and variation in disease: Review. Issue 8 (August 1983) Authors: Rand-Weaver, Mariann; Price, Robert G. Journal: Bioscience reports Issue: Volume 3:Issue 8(1983) Page Start: 713 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Prospective Italian real‐world study of mepolizumab in severe eosinophilic asthma validates retrospective outcome reports. Issue 8 (14th October 2021) Authors: Pini, Laura; Caruso, Cristiano; Colantuono, Stefania; Bagnasco, Diego; Maxwell, Aoife; Price, Robert G.; Howarth, Peter; Canonica, Giorgio Walter Journal: Clinical and translational allergy Issue: Volume 11:Issue 8(2021) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma. Issue 12 (9th September 2019) Authors: Gupta, Atul; Pouliquen, Isabelle; Austin, Daren; Price, Robert G.; Kempsford, Rodger; Steinfeld, Jonathan; Bradford, Eric S.; Yancey, Steven W. Journal: Pediatric pulmonology Issue: Volume 54:Issue 12(2019) Page Start: 1957 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗